Vor Biopharma VOR

Jean-Paul Kress, M.D., age 60, has served as our President and Chief Executive Officer and as Chairman of our Board since June 2025. Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He is the Chief Executive Officer and Chairman of Vor Bio (www.vorbio.com) a biotech company reinventing the treatment of autoimmune diseases by tackling it as its root through the development of its lead asset telitacicept. Previously, he served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi (tafasitamab), and advanced the company's pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys' position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies. He also served on the board of directors of Erytech from 2019 to 2023, and of Sarepta from 2015 to 2017. Dr Kress holds graduate and post-graduate degrees in biochemistry and molecular and cellular pharmacology from Ecole normale superieure, Paris, and an M.D. from Faculte Necker-Enfants Malades, Paris.

Sandesh Mahatme, age 61, has served as our Chief Financial Officer since July 2025. From July 2020 to June 2024, Mr. Mahatme served as President, Chief Operating Officer and Chief Financial Officer of National Resilience Inc., a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. From November 2012 to July 2020, Mr. Mahatme served in various executive positions, including as Executive Vice President, Chief Financial Officer and Chief Business Officer of Sarepta Therapeutics, Inc., a publicly traded biopharmaceutical company. Prior to those roles, he worked at Celgene Corporation, where he served in various positions including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. Mr. Mahatme served in senior roles in business development and corporate finance at Pfizer after starting his career at Ernst & Young LLP. Mr. Mahatme has served as a director of Idorsia Pharmaceuticals Ltd. since May 2020 and of CRISPR Therapeutics AG since May 2024. In addition, Mr. Mahatme previously served as a director on the boards of Aeglea BioTherapeutics, Inc. from June 2015 to July 2022 and Flexion Therapeutics, Inc. from July 2014 to June 2021. Mr. Mahatme earned Master of Laws degrees from Cornell Law School and the New York University School of Law and is a member of the New York State Bar Association.

The Board appointed Qing Zuraw as the Company's Chief Development Officer, effective as of July 17, 2025. Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd. from December 2022 to July 2025, where she was one of the key leaders of the successful development and execution of clinical trials for telitacicept across four key indications- systemic lupus erythematosus (SLE), Sjogren's syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA)- culminating in regulatory approvals in China for the treatment of SLE, generalized MG and RA. Dr. Zuraw has also previously held senior leadership roles at Janssen Research & Development from December 2018 to December 2022, Teva Pharmaceutical Industries Ltd. from August 2017 to December 2018, and Akebia Therapeutics, Inc. from June 2015 to July 2017, where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas. Dr. Zuraw earned her M.D. and M.B.A. from Drexel University.

Erez Kalir, age 54, has served as a member of our Board since January 2025. Mr. Kalir has served as chief operating officer and a board member of Manas AI since January 2024, as founder and chief executive officer of Martial Eagle Fund since May 2019 and as venture partner with FJ Labs since November 2021. Mr. Kalir received an A.B. in English and biology from Stanford University, an MSc. in Biology from University of Oxford and a J.D. from Yale Law School.

Alexander (Bo) Cumbo, age 55, has served as a member of our Board since July 2025. Mr. Cumbo has served as President and Chief Executive Officer of Solid Biosciences since December 2022. Prior to that, he served as President and Chief Executive Officer of AavantiBio from October 2020 to December 2022. Prior to that, he served in roles of increasing responsibility at Sarepta Therapeutics from January 2013 to September 2020, most recently serving as Executive Vice President, Chief Commercial Officer. He currently serves as a Board Member of Climb Bio and recently at Verve Therapeutics and RA Pharma. Mr. Cumbo received his Bachelor of Science in Laboratory Technology from Auburn University.

Michel Detheux, Ph.D., age 59, has served as a member of our Board since July 2025. Dr. Detheux currently serves as the Chief Executive Officer of iTeos Therapeutics. He co-founded iTeos in 2011 then has led the company from its preclinical origins to late- stage clinical development, financially raising $1.2 billion since inception, including a NASDAQ IPO in 2020 and one of the largest upfront strategic deals ever for an early-stage asset with GlaxoSmithKline to co-develop and co-commercialize belrestotug, iTeos' differentiated anti-TIGIT antibody, in 2021. Prior to founding iTeos, he served as a Director at Ludwig Cancer Research. Dr. Detheux began his career at Ogeda (f/k/a Euroscreen) where he worked in various scientific and business development roles. Michel currently serves as Chairman of the Board at Egle Therapeutics. Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Universite Catholique de Louvain, and a business certificate from Solvay Business School.

Daniella Beckman, age 47, has served as a member of our Board since July 2020 and as lead independent director since March 2026. From September 2019 to April 2026, she served as the Chief Financial Officer of Tango Therapeutics, a targeted oncology biotechnology company. From November 2015 to September 2019, she provided consulting services and served as the Interim Chief Financial Officer for several early-stage biotechnology companies. Ms. Beckman previously served on the board of directors of Blueprint Medicines Corp, from December 2021 to July 2025, until its acquisition by Sanofi, and previously served on the board of directors of Translate Bio, Inc., from October 2017 to September 2021, until its acquisition by Sanofi and previously served on the board of directors of 5:01 Acquisition Corp, a special purpose acquisition company, from October 2020 to October 2022. She currently serves on the board of directors of Upstream Bio, a public company, since December 2021. Ms. Beckman received a B.S. in business administration-accounting from Boston University.

Fouad Namouni, M.D., age 57, has served as a member of our Board since April 2024. Dr. Namouni has served as President, Research and Development of Blueprint Medicines Corporation, a global biopharmaceutical company, from September 2020 until its acquisition by Sanofi in 2025. Prior to Blueprint, Dr. Namouni served in various leadership roles at Bristol Myers Squibb Company since 1999, most recently as Senior Vice President and Head of Oncology Development from August 2016 to April 2020 with the responsibility for driving product development plans across a portfolio of drug candidates. Previously, Dr. Namouni served as Head of Global Medical Affairs at BMS from September 2015 to September 2017 and Head of Development at BMS for OPDIVO (nivolumab) and YERVOY (ipilimumab) from January 2011 to September 2015. Dr. Namouni previously served as a member of the board of directors of Aprea Therapeutics Inc. from June 2020 to May 2022. Dr. Namouni has more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. He holds an M.D. from the University of Annaba Medical School in Algeria and a Pediatrics degree from Universite Rene Descartes in Paris, France. Additionally, Dr. Namouni received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Universite Paris-Sud in France.

Wouter Joustra, age 37, has served as a member of our Board since December 2025. Wouter Joustra is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Joustra is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion's Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies. Prior to joining Forbion in 2019, Mr. Joustra previously was a Senior Trader, as well as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. Mr. Joustra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion's SPAC vehicle until the completion of the business combination of enGene Holdings Inc. (NASDAQ: ENGN) in October 2023. Currently Mr. Joustra serves on the board of directors of VectorY Therapeutics, NewAmsterdam Pharma N.V. (NASDAQ: NAMS), Beacon Therapeutics, Navigator Medicines and Verdiva Bio. Mr. Joustra holds an M.Sc. in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.

On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to serve on the Board as an independent director. Dr. Zaccardelli has served as Founder and Managing Member of Bull City Select Investments, LLC since 2016. From 2020 to 2025, Dr. Zaccardelli served as President and Chief Executive Officer and as a director of Verona Pharma plc, a public pharmaceutical company developing ensifentrine for respiratory diseases, until its acquisition by Merck & Co., Inc. in October 2025. From 2018 to 2019, he served as President and Chief Executive Officer and as a director of Dova Pharmaceuticals, Inc., a public pharmaceutical company with the commercial product Doptelet for thrombocytopenia, which was acquired by Sobi in 2019. From 2016 to 2017, he served as Interim Chief Executive Officer and as a director of Cempra Pharmaceuticals, Inc., a public pharmaceutical company focused on antimicrobial therapeutics, which was acquired by Melinta Therapeutics LLC in 2017. Dr. Zaccardelli holds a Doctor of Pharmacy degree from the University of Michigan and completed a fellowship in clinical research and drug development at the University of North Carolina.

Jeremy Sokolove, M.D., age 52, has served as our Chief Medical Officer since November 2025. Prior to joining Vor Bio, Dr. Sokolove served as Chief Medical Officer In-Residence at Roivant Sciences from September 2024 to November 2025, where he led strategic assessment and in-licensing of novel therapeutic programs and provided clinical and operational leadership across Roivant's portfolio companies. Previously, he served as Chief Medical Officer at Odyssey Therapeutics from September 2023 to September 2024, guiding the company's transition to a clinical-stage organization developing next-generation immunomodulators for autoimmune and inflammatory diseases. Earlier in his career, Dr. Sokolove held senior leadership positions at GlaxoSmithKline as Senior Vice President and Head of Clinical Pharmacology & Experimental Medicine, and at AbbVie as Head of Immunology Translational Science. Dr. Sokolove was previously on the faculty at Stanford University Medical Center. He earned his M.D. from Boston University School of Medicine and completed his Internal Medicine residency at Boston University Medical Center, where he served as Chief Medical Resident. He completed clinical and research fellowships in Rheumatology and Immunology at Stanford University.